Calin Badea, MD
Internal Medicine · Hinesville, GANPI 1346239639
Payments from drug & device makers
Across 333 payments — averaging $15.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$875
- AstraZeneca$735
- AbbVie$693
- Lilly USA, LLC$390
- Boehringer Ingelheim$290
- Amgen$205
- plus $2K from 31 others
What the payments were for
- Food & beverage$5,07199%
- Education$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 69 | $875 |
| AstraZeneca | 45 | $735 |
| AbbVie(2 entities) | 55 | $693 |
| Lilly USA, LLC | 24 | $390 |
| Boehringer Ingelheim | 18 | $290 |
| Amgen | 11 | $205 |
| Pfizer | 12 | $180 |
| Johnson & Johnson | 10 | $166 |
| Novartis | 10 | $159 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $154 |
| GSK | 10 | $141 |
| Boston Scientific | 5 | $124 |
| Sanofi-aventis U.S. LLC | 7 | $117 |
| Otsuka America Pharmaceutical, Inc. | 4 | $85 |
| Astellas Pharma US Inc | 4 | $75 |
| Merck | 4 | $72 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $67 |
| Bayer | 3 | $62 |
| Inspire Medical Systems, Inc. | 2 | $61 |
| Shire North American Group Inc | 3 | $51 |
| Vanda Pharmaceuticals Inc. | 2 | $48 |
| Biohaven Pharmaceuticals, Inc. | 3 | $47 |
| Biogen | 2 | $37 |
| Esperion Therapeutics, Inc. | 2 | $35 |
| Dexcom, Inc. | 2 | $32 |
| Exact Sciences | 2 | $29 |
| Gilead | 1 | $26 |
| Neurelis, Inc. | 1 | $26 |
| Daiichi Sankyo Inc. | 1 | $22 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
| Smith+Nephew | 1 | $19 |
| VBI Vaccine (delaware) Inc. | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $14 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $14 |
| Abbott | 1 | $14 |
How this compares
$5,130 in reported general payments places this provider in the 85th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 389 | $395,364 |
| EliquisApixaban | 340 | $237,348 |
| OzempicSemaglutide | 208 | $226,791 |
| FarxigaDapagliflozin Propanediol | 216 | $213,540 |
| TrulicityDulaglutide | 122 | $165,648 |
| LinzessLinaclotide | 121 | $82,849 |
| MounjaroTirzepatide | 63 | $71,109 |
| EntrestoSacubitril/Valsartan | 71 | $69,113 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 59 | $53,511 |
| XareltoRivaroxaban | 36 | $41,248 |
| Tresiba Flextouch U-200Insulin Degludec | 17 | $23,408 |
| Tresiba Flextouch U-100Insulin Degludec | 31 | $22,409 |
| JanuviaSitagliptin Phosphate | 27 | $21,304 |
| VraylarCariprazine Hcl | 13 | $17,955 |
| RybelsusSemaglutide | 13 | $16,557 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $290 | $395,364389 claims |
| Novo NordiskOzempic, Rybelsus | $875 | $243,348221 claims |
| PfizerEliquis | $180 | $237,348340 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $390 | $236,757185 claims |
| AstraZenecaFarxiga, Symbicort | $735 | $219,330241 claims |
| AbbVieLinzess, Vraylar, Ubrelvy | $693 | $111,598145 claims |
| NovartisEntresto | $159 | $69,11371 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $141 | $65,24284 claims |
| Johnson & JohnsonXarelto, Risperdal Consta | $166 | $50,76668 claims |
| MerckJanuvia | $72 | $21,30427 claims |
| Smith+NephewSantyl | $19 | $4,58315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Hinesville
- Robert CarterHinesville$1.1M
- Paul BradleySavannah$76.4M
- Kimball JohnsonAtlanta$51.1M
- Bram WieskopfWoodstock$21.9M
- Dwight BlakeUnion City$13.3M
- Charlotte Grayson-MathisFayetteville$9.6M
- Christopher RecknorGainesville$9.2M
- James HarperJohns Creek$9.2M
- Robert Springer IiiAtlanta$5.3M
- Thomas MoriaritySavannah$4.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.